William J. Sandborn - Jul 3, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Jul 3, 2023
Transactions value $
-$438,779
Form type
4
Date filed
7/5/2023, 08:16 PM
Previous filing
Jun 27, 2023
Next filing
Aug 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Options Exercise $177K +11.9K +24.59% $14.85 60.3K Jul 3, 2023 Direct
transaction VTYX Common Stock Sale -$476K -11.9K -19.74% $40.00 48.4K Jul 3, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$139K -3.49K -11.19% $40.00 27.7K Jul 3, 2023 By Spouse F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Stock Option (Right to Buy) Options Exercise $0 -11.9K -1.7% $0.00 688K Jul 3, 2023 Common Stock 11.9K $14.85 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
F2 Represents the weighted average share price of an aggregate total of 11,900 shares sold in the price range of $40.00 to $40.04. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's spouse on December 19, 2022.
F4 Represents the weighted average share price of an aggregate total of 3,487 shares sold in the price range of $40.00 to $40.02. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022.

Remarks:

President and Chief Medical Officer